Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early-onset Dupilumab Effects in CRSwNP
NCT06188871Phase 4Withdrawn
- Sponsor
- University of Rochester
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by University of Rochester. Planned start Jun 2024; status: withdrawn.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06188871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188871.